Guardant Health, Inc. has announced significant findings from the Phase III SERENA-6 trial, demonstrating the clinical effectiveness of the Guardant360® CDx test in guiding treatment for breast cancer. The study showed that using a circulating tumor DNA-guided approach, the Guardant360 CDx test can detect emerging resistance in 1st-line therapy before radiological disease progression in advanced breast cancer. Results indicated that AstraZeneca's camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer who had an emergent ESR1 tumor mutation. These findings, presented at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine, highlight a new paradigm in using liquid biopsy to inform timely treatment changes, potentially improving patient outcomes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.